HCP Live: The Significance of DAPA-HF for Cardiovascular Care and Beyond
To say that SGLT-2 inhibitor dapagliflozin has made great strides in cardiovascular care is an understatement.
Data has supported the drug’s ability to provide glycemic benefit among patients with diabetes, and recent trials have only bolstered its promise in improving cardiometabolic, cardiovascular, and renal outcome
HCP Live talked to Dr. Mikhail Kosiborod, director of Cardiometabolic Research at Saint Luke's Mid America Heart Institute and vice president of research at Saint Luke's Health System, about the clinical impact of the DAPA-HF trial.
Read the full HCP Live article: The Significance of DAPA-HF for Cardiovascular Care and Beyond